1 / 25

Dirk Blom, Tomas Hala, Michael Bolognese, Michael J Lillestol, Phillip D Toth, Lesley Burgess, Richard Ceska , Eli Rot

Long-term Tolerability and Efficacy of Evolocumab (AMG 145) in Hyperlipidemic Subjects: A 52 Week Phase 3 Double-blind, Randomized, Placebo-controlled Study. Dirk Blom, Tomas Hala, Michael Bolognese, Michael J Lillestol, Phillip D Toth, Lesley Burgess, Richard Ceska , Eli Roth,

brenna
Download Presentation

Dirk Blom, Tomas Hala, Michael Bolognese, Michael J Lillestol, Phillip D Toth, Lesley Burgess, Richard Ceska , Eli Rot

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Long-term Tolerability and Efficacy of Evolocumab (AMG 145) in Hyperlipidemic Subjects: A 52 Week Phase 3 Double-blind, Randomized, Placebo-controlled Study Dirk Blom, Tomas Hala, Michael Bolognese, Michael J Lillestol,Phillip D Toth, Lesley Burgess, Richard Ceska, Eli Roth, Michael J Koren, Maria Laura Monsalvo, Kate Tsirtsonis, Jae B Kim, Scott M Wasserman, Rob Scott, Christie M Ballantyne, Evan A Stein, for the DESCARTES Investigators March 29, 2014, Featured Clinical Research Session 400 American College of Cardiology, Washington DC

  2. Background: PCSK9 Inhibition • PCSK9 is a well validated therapeutic target based on gain and loss of function human genetic abnormalities, Mendelian randomization studies, and its recently elucidated role in LDL receptor function and regulation of LDL cholesterol. • Evolocumab (AMG 145), a fully human monoclonal antibody against PCSK9, reduced LDL-C by up to 65% and was well tolerated in 4 randomized, placebo-controlled, phase 2 clinical trials of 12 weeks duration in over 1300 hypercholesterolemic patients.1-4 • An open label extension study of patients from phase 2 trials with evolocumab (OSLER) recently reported 1 year safety and efficacy data.5 • Lancet. 2012;380:1995-2006 • Circulation. 2012;126:2408-2417 • JAMA. 2012;308:2497-2506 • Lancet. 2012;380:2007-2017 • Circulation 2014;129:234-243

  3. The DESCARTES Study • Durable Effect of PCSK9 antibody CompARedwiThplacEboStudy (NCT01516879) • A 52 week global, randomized, double-blind, placebo-controlled multicenter study to provide longer term data on the efficacy and safety of evolocumab • Included patients with a wide range of cardiovascular risk • Lipid-lowering therapy, ranging from diet alone to atorvastatin 80 mg plus ezetimibe, was optimized to reach NCEP ATP III LDL-C treatment goals

  4. DESCARTES: Endpoints • Primary: % change from baseline in LDL-C measured by ultracentrifugation (UC) at week 52 • Secondary • %change from baseline in UC LDL-C at week 12 • Change from baseline in UC LDL-C at week 52 • % of patients with UC LDL-C < 70 mg/dL at week 52 • %changes from baseline for TC, HDL-C, ApoB, VLDL-C, triglycerides, and Lp(a) at week 52 • % changes in total cholesterol/HDL cholesterol ratio and apolipoprotein B/apolipoprotein A1 ratio at week 52

  5. DESCARTES: Patients • Adults aged 18 to 75 years • Screening • LDL-C ≥75 mg/dL and TG ≤ 400 mg/dL • Exclusion: LDL-C ≤ 99 mg/dL with CHD or risk equivalent and not receiving a statin • Following lipid stabilization period • At NCEP ATP III target or receiving maximal therapy (atorvastatin 80 mg plus ezetimibe 10 mg) • LDL-C ≥ 75 mg/dL

  6. DESCARTES: Screening and Lipid Stabilization Screening LDL-C ≥ 75 mg/dL Initial LDL-C < 75 mg/dL = Screen Fail • Background Therapy Assigned Based on • CV Risk, LDL-C, and Current Therapy: • Diet alone • Diet and atorvastatin 10 mg • Diet and atorvastatin 80 mg • Diet, atorvastatin 80 mg, and ezetimibe10 mg Screening Period 4 Weeks to 16 Weeks Up-titrate Background Therapy 4 Week Dietary Run-in and Lipid Stabilization No • CHD/risk equivalent: LDL < 100 mg/dL OR • No CHD/risk equivalent: LDL < 130 mg/dL OR • On Maximal background therapy LDL < 75 mg/dL = Screen Fail (except on maximal background therapy – allowed one downtitration Yes • Randomization 2:1 (~900 Subjects) • Evolocumab 420 mg SC QM • Placebo SC QM

  7. DESCARTES: Study Overview Lipid Stabilization Period Fasting LDL-C 5–10 days before randomization Randomization 2:1 End of Study Screening - Assign background Rx based on CV risk, LDL, and +/- prior statin: No drug Low dose: 10 mg atorvastatin High dose: 80 mg atorvastatin Maximal: 80 mg atorvastatin + 10 mg ezetimibe Subcutaneous injection of 6 mL Placebo Placebo SC QM n = 303 Evolocumab 420 mg SC QM n = 602 Period = Max. 16 weeks / Min: 4 weeks Day 1 Week 4 Week 52* Week 8 Visits: Study Drug (Evolocumab or Placebo) QM: * Last dose administered at week 48

  8. DESCARTES: Patient Disposition Screened: 2120 635 screen failures 1485 entered lipid stabilization period 580 lipid stabilization period failures 905 randomized to evolocumab or placebo

  9. DESCARTES: Patient Disposition II 905 Randomized 2:1 allocation to evolocumab or placebo 112 Diet alone (38 P: 74 Evo) 385 Atorvastatin 10 (129 P: 256 Evo) 219 Atorvastatin 80 (73 P: 146 Evo) 189 Atorvastatin 80 + Ezetimibe 10 (63 P: 126 Evo) 73 discontinued evolocumab 28 discontinued placebo 4 never received SD* 800 completed 52 weeks of Study Drug E = Ezetimibe, Evo = Evolocumab, P = Placebo * Study Drug

  10. DESCARTES: Baseline Characteristics A = Atorvastatin E = Ezetimibe Full Analysis Set (FAS) data presented: Patients who received at least one dose of study drug

  11. DESCARTES: Baseline Patient Characteristics II A = Atorvastatin E = Ezetimibe

  12. DESCARTES: Baseline Lipids *UC = ultracentrifugation

  13. DESCARTES: Baseline LDL-C on Background Therapy Prior to First Dose of Study Drug A = Atorvastatin E = Ezetimibe EVO = Evolocumab P = Placebo

  14. DESCARTES: % Change in UC LDL-C From Baseline - FAS 20 6.0% 10 0 -10 Treatment difference 57% -20 UC LDL-C Percent Change from Baseline, Mean (± SE) -30 -40 -50 -51.5% -60 -70 Number of patients: -80 302 294 264 599 582 542 Baseline Week 12 Week 52 Study Week Placebo QM (N = 302) Evolocumab 420 mg QM (N = 599) FAS = Full analysis set, UC = ultracentrifugation

  15. DESCARTES: % Change in UC LDL-C from Baseline at Week 52 Atorvastatin 80 mg + Ezetimibe 10 mg Atorvastatin 10 mg Atorvastatin 80 mg Diet Alone Overall Placebo Evolocumab Treatment Difference Error bars represent standard error for treatment difference Treatment difference are least squares mean derived from a repeated measures model

  16. DESCARTES: UCLDL-C Goal Achievement LDL-C < 70 mg/dL at Week 52 Diet + Atorvastatin 80 mg + Ezetimibe 10 mg Diet + Atorvastatin 10 mg Diet + Atorvastatin 80 mg Diet Alone Total

  17. Changes in Mean Levels of Unbound PCSK9 Evolocumab Placebo 700 Atorvastatin 80 mg Diet Only Atorvastatin 80 mg + Ezetimibe 10 mg Atorvastatin 10 mg 600 500 400 Mean ± SE PCSK9 Level, ng/mL 300 200 100 0 Baseline Week 12 Week 13 Week 52 4 weeks post-dose 1 week post-dose 4 weeks post dose

  18. DESCARTES: Other Lipids at Week 52 6% 2% 10 ApoB HDL-C 6 0 -10 4 Percent Change from Baseline, Mean (%) Percent Change from Baseline, Mean (%) -20 0 2 -30 0 -40 -42% -50 -2 0 ApoA1 Lp(a) 2% -5 3 -6% (-21 to 1) -10 2 Percent Change from Baseline, Median (%) -15 1 Percent Change from Baseline, Mean (%) -20 0 -25 -30 -1 -28% (-49 to -6) -2 -1% 3% (-17 to 25) 6 Triglycerides 4 2 Placebo QM 0 Percent Change from Baseline, Median (%) -2 Evolocumab 420 mg QM -4 -6 -8 Error bars represent standard errorData in parentheses represent Q1 to Q3 -9% (-26 to 13) -10

  19. DESCARTES: Safety and Tolerability

  20. DESCARTES: Treatment Emergent Adverse Events Treatment emergent adverse events are adverse events occurring between the first dose of Study Drug and End of Study

  21. DESCARTES: Treatment Emergent Adverse Events II Treatment emergent adverse events are adverse events occurring between the first dose of Study Drug and End of Study

  22. DESCARTES: Hepatic and Muscle Safety * At any visit post baseline, TEAE = treatment emergent adverse event

  23. DESCARTES: Glycemic Parameters Changes from baseline at week 52 A = Atorvastatin E = Ezetimibe

  24. DESCARTES: Injection Sites and Antibodies • Potential injection site reactions • Evolocumab 34 (5.7%) • Placebo 15 (5.0%) • Antibodies to evolocumab • 2 patients (allocated to evolocumab) had binding antibodies prior to evolocumab exposure • One patient on evolocumab developed transient binding antibodies during therapy • No neutralizing antibodies detected throughout study

  25. DESCARTES: Conclusions • Largest and longest double-blind, randomized placebo controlled trial reported to date, of a monoclonal antibody to PCSK9 • Evolocumab 420 mg QM reduced placebo adjusted UC LDL-C 57% from baseline in patients with a wide range of cardiovascular risk receiving background lipid lowering therapies ranging from diet alone to the combination of atorvastatin 80 mg/d and ezetimibe 10 mg/d • Durable effect with consistent LDL-C reductions at weeks 12 and 52 • Similar AE profile in placebo and active treatment groups • No adverse laboratory signals observed • Cardiovascular outcome trial is ongoing

More Related